Christopher Rovaldi - Apr 6, 2022 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Chief Operating Officer
Signature
/s/ Esther Cho, Attorney-in-Fact
Stock symbol
KROS
Transactions as of
Apr 6, 2022
Transactions value $
-$84,672
Form type
4
Date filed
4/8/2022, 04:21 PM
Previous filing
Apr 5, 2022
Next filing
Feb 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Options Exercise $27.6K +1.73K $16.00 1.73K Apr 6, 2022 Direct
transaction KROS Common Stock Sale -$112K -1.73K -100% $65.00 0 Apr 6, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Employee Stock Option (right to buy) Options Exercise $0 -1.73K -17.76% $0.00 8K Apr 6, 2022 Common Stock 1.73K $16.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 One-fourth (1/4th) of the shares subject to the option vested on January 1, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.